0000950170-24-041527.txt : 20240403 0000950170-24-041527.hdr.sgml : 20240403 20240403204743 ACCESSION NUMBER: 0000950170-24-041527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Noonberg Sarah B. CENTRAL INDEX KEY: 0001706301 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41949 FILM NUMBER: 24821261 MAIL ADDRESS: STREET 1: 331 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Metagenomi, Inc. CENTRAL INDEX KEY: 0001785279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813909017 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5959 HORTON STREET STREET 2: 7TH FLOOR CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 871-4880 MAIL ADDRESS: STREET 1: 5959 HORTON STREET STREET 2: 7TH FLOOR CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Metagenomi Technologies, LLC DATE OF NAME CHANGE: 20190812 4 1 ownership.xml 4 X0508 4 2024-04-01 0001785279 Metagenomi, Inc. MGX 0001706301 Noonberg Sarah B. C/O METAGENOMI, INC. 5959 HORTON STREET, 7TH FLOOR EMERYVILLE CA 94608 false true false false Chief Medical Officer false Common Stock 2024-04-01 4 A false 57763 0.00 A 100374 D Stock Option (Right to Buy) 10.82 2024-04-01 4 A false 242875 0 A 2034-03-31 Common Stock 242875 242875 D These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. /s/ Matthew L. Wein, attorney-in-fact 2024-04-03